CRVS
Price:
$4.03
Market Cap:
$252.08M
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for p...[Read more]
Industry
Biotechnology
IPO Date
2016-03-23
Stock Exchange
NASDAQ
Ticker
CRVS
According to Corvus Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -9.60. This represents a change of 129.92% compared to the average of -4.18 of the last 4 quarters.
The mean historical PE Ratio of Corvus Pharmaceuticals, Inc. over the last ten years is -6.71. The current -9.60 PE Ratio has changed 14.21% with respect to the historical average. Over the past ten years (40 quarters), CRVS's PE Ratio was at its highest in in the December 2020 quarter at 0.96. The PE Ratio was at its lowest in in the March 2015 quarter at -38.00.
Average
-6.71
Median
-3.73
Minimum
-21.76
Maximum
-0.79
Discovering the peaks and valleys of Corvus Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 496.19%
Maximum Annual PE Ratio = -0.79
Minimum Annual Increase = -87.86%
Minimum Annual PE Ratio = -21.76
Year | PE Ratio | Change |
---|---|---|
2023 | -3.13 | 295.53% |
2022 | -0.79 | -70.06% |
2021 | -2.64 | -87.86% |
2020 | -21.76 | 496.19% |
2019 | -3.65 | 69.68% |
2018 | -2.15 | -43.59% |
2017 | -3.81 | -37.10% |
2016 | -6.06 | -34.67% |
2015 | -9.28 | -32.72% |
The current PE Ratio of Corvus Pharmaceuticals, Inc. (CRVS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-2.19
5-year avg
-6.39
10-year avg
-6.71
Corvus Pharmaceuticals, Inc.’s PE Ratio is greater than Mereo BioPharma Group plc (-18.18), less than Terns Pharmaceuticals, Inc. (-6.06), less than PDS Biotechnology Corporation (-2.64), less than Inozyme Pharma, Inc. (-3.48), less than HOOKIPA Pharma Inc. (-1.22), less than X4 Pharmaceuticals, Inc. (7.41), less than Day One Biopharmaceuticals, Inc. (-7.39), less than Acumen Pharmaceuticals, Inc. (-2.06),
Company | PE Ratio | Market cap |
---|---|---|
-18.18 | $664.26M | |
-6.06 | $549.60M | |
-2.64 | $107.88M | |
-3.48 | $312.42M | |
-1.22 | $159.50M | |
7.41 | $109.78M | |
-7.39 | $1.25B | |
-2.06 | $133.38M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Corvus Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Corvus Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Corvus Pharmaceuticals, Inc.'s PE Ratio?
How is the PE Ratio calculated for Corvus Pharmaceuticals, Inc. (CRVS)?
What is the highest PE Ratio for Corvus Pharmaceuticals, Inc. (CRVS)?
What is the 3-year average PE Ratio for Corvus Pharmaceuticals, Inc. (CRVS)?
What is the 5-year average PE Ratio for Corvus Pharmaceuticals, Inc. (CRVS)?
How does the current PE Ratio for Corvus Pharmaceuticals, Inc. (CRVS) compare to its historical average?